{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:11:36Z","timestamp":1790259096136,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ahj.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T20:52:23Z","timestamp":1423687943000},"page":"631-638.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo"],"prefix":"10.1016","volume":"169","clinical-trial-number":[{"clinical-trial-number":"nct01144338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01147250","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01179048","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01394952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01720446","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rhonda","family":"Bentley-Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hertzel C.","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars V.","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Probstfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ahj.2015.02.002_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ahj.2015.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study","volume":"115","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.02.002_bb0015","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-147-3-200708070-00167","article-title":"Mortality trends in men and women with diabetes, 1971 to 2000","volume":"147","author":"Gregg","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2015.02.002_bb0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ahj.2011.07.015","article-title":"Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both","volume":"162","author":"Shah","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2015.02.002_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurjhf\/hfr125","article-title":"Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren","volume":"14","author":"Shah","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2015.02.002_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11883-010-0153-0","article-title":"Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies","volume":"13","author":"Addison","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2015.02.002_bb0040","article-title":"Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","year":"2008"},{"key":"10.1016\/j.ahj.2015.02.002_bb0045","article-title":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.ahj.2015.02.002_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/CH-2011-1479","article-title":"Chronic pharmacological preconditioning against ischemia","volume":"49","author":"Luca","year":"2011","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.ahj.2015.02.002_bb0055","first-page":"56","article-title":"Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs","volume":"60","author":"Panicker","year":"2012","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ahj.2015.02.002_bb0060","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0070","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2015.02.002_bb0080","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ahj.2015.02.002_bb0085","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2015.02.002_bb0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","article-title":"Systematic review: glucose control and cardiovascular disease in type 2 diabetes","volume":"151","author":"Kelly","year":"2009","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.ahj.2015.02.002_bb0095","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ahj.2015.02.002_bb0100","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2015.02.002_bb0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2015.02.002_bb0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2015.02.002_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2337\/diab.38.3.338","article-title":"Glucagonlike peptide I (7-37) actions on endocrine pancreas","volume":"38","author":"Weir","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2015.02.002_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CE.S15525","article-title":"Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes","volume":"6","author":"Barnett","year":"2011","journal-title":"Core Evid"},{"key":"10.1016\/j.ahj.2015.02.002_bb0130","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2015.02.002_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.ahj.2015.02.002_bb0140","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2015.02.002_bb0145","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2015.02.002_bb0150","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2015.02.002_bb0155","first-page":"25","article-title":"Lixisenatide as add-on therapy to basal insulin","volume":"8","author":"Brown","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ahj.2015.02.002_bb0160","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1517\/14656566.2013.838559","article-title":"Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus","volume":"14","author":"Forst","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ahj.2015.02.002_bb0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdiacomp.2013.10.003","article-title":"Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials","volume":"28","author":"Raccah","year":"2014","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ahj.2015.02.002_bb0170","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2015.02.002_bb0175","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1161\/01.CIR.0000142047.28024.F2","article-title":"Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial","volume":"110","author":"Aguilar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.02.002_bb0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.02.002_bb0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11886-010-0118-5","article-title":"Acute coronary syndrome in the patient with diabetes: is the management different?","volume":"12","author":"Amin","year":"2010","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ahj.2015.02.002_bb0190","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1161\/CIRCULATIONAHA.108.813501","article-title":"Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel","volume":"118","author":"Fuster","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.02.002_bb0195","article-title":"Screening for type 2 diabetes: report of a World Health Organization and International Diabetes Federation meeting","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.ahj.2015.02.002_bb0200","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2015.02.002_bb0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.02.002_bb0210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies","volume":"11","author":"Wohlfart","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.ahj.2015.02.002_bb0215","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.02.002_bb0220","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2015.02.002_bb0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ahj.2015.02.002_bb0230","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ahj.2015.02.002_bb0235","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1753-0407.2010.00082.x","article-title":"Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)","volume":"2","author":"Erdmann","year":"2010","journal-title":"J Diabetes"},{"issue":"9681","key":"10.1016\/j.ahj.2015.02.002_bb0240","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.02.002_bb0245","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2015.02.002_bb0250","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ahj.2015.02.002_bb0255","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2015.02.002_bb0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","article-title":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","volume":"166","author":"Green","year":"2013","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2015.02.002_bb9000","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031500099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031500099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:53:52Z","timestamp":1757570032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031500099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S000287031500099X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.02.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}